Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00627861 · ClinicalTrials.gov registry record · NA
Combined Renin Inhibition/Beta-blockade
A NA study, sponsored by The Rogosin Institute.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00627861: Clinical Trial NA study, sponsored by The Rogosin Institute.
NCT00627861 is a NA study that was terminated before completion, run by The Rogosin Institute. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00627861, a NA study, was terminated before completion, sponsored by The Rogosin Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Antihypertensive drug treatment is effective in only about 50% of patients. One mechanism responsible for treatment failure is a drug related stimulation of the renin-angiotension-aldosterone-system (RAAS). Several classes of medications that treat hypertension by blocking the RAAS system have been developed. However, the kidney responds to these drug treatments by producing greater amounts of renin. This high level of renin can reduce the effectiveness of some of these medications, ultimately causing the blood pressure to rise. This is one reason why blood pressure can be difficult to control in a certain percentage of patients. The hypothesis to be tested in the proposed study is that beta-adrenergic blockade (β-blockade), when superimposed upon aliskiren, a drug that competitively inhibits plasma renin activity (PRA) but stimulates the release of renin by the kidneys (plasma renin concentration \[PRC\]), can suppress the reactive increase in PRC that occurs during aliskiren monotherapy. The primary aim of this study is to measure plasma renin concentration (PRC) and plasma renin activity (PRA) levels during renin inhibition with aliskiren and combined renin inhibition/β-blocker treatment to determine whether the addition of a β-blocker attenuates the rise in plasma renin concentration (PRC). A secondary aim is to determine whether combined treatment further suppresses PRA and blood pressure.
Interventions
- DRUG Aliskiren
- DRUG Extended-release metoprolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-05 |
| Phase | NA |
Why NCT00627861 stopped before completion
NCT00627861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Aliskiren is the first listed.
NCT00627861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00627861 about?
NCT00627861 is a clinical study titled "Combined Renin Inhibition/Beta-blockade". Antihypertensive drug treatment is effective in only about 50% of patients. One mechanism responsible for treatment failure is a drug related stimulation of the renin-angiotension-aldosterone-system (RAAS). Several classes of medications that treat hypertension by blocking the RAAS system have been ...
What is the current status of trial NCT00627861?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2008-11. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00627861?
The interventions under investigation include: Aliskiren (DRUG), Extended-release metoprolol (DRUG).
Who is sponsoring clinical trial NCT00627861?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00627861's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia